1
|
Bartos MN, Scott SA, Jabs EW, Naik H. Attitudes on pharmacogenomic results as secondary findings among medical geneticists. Pharmacogenet Genomics 2022; 32:273-280. [PMID: 35916546 DOI: 10.1097/fpc.0000000000000479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
OBJECTIVES As evidence mounts supporting the utility of pharmacogenomic-guided medication management, incorporating pharmacogenomic genes into secondary finding results from sequencing panels is increasingly under consideration. We studied medical geneticists' attitudes on receiving pharmacogenomic results as secondary finding. METHODS Four focus groups with 16 medical geneticists total were conducted followed by thematic analysis. RESULTS All participants ordered genetic sequencing tests; however, the majority had rarely or never ordered pharmacogenomic tests (10/16) or prescribed medications with established response variability (11/16). In total 81.3% expressed low comfort interpreting pharmacogenomic results without appropriate clinical resources (13/16). The positives of receiving pharmacogenomic results as secondary finding included prevention of adverse drug reactions in adults, grateful information-seeking patients, the ability to rapidly prescribe more effective treatments and appreciation of the recent advances in both pharmacogenomic knowledge and available guidelines. Negatives included laboratory reporting issues, exclusivity of pharmacogenomic results to certain populations, lengthy reports concealing pharmacogenomic results in patient charts and laboratories marketing to individuals without prior pharmacogenomic knowledge or targeting inappropriate populations. The most desirable pharmacogenomic resources included a universal electronic health record clinical decision support tool to assist identifying and implementing pharmacogenomic results, a specialized pharmacist as part of the care team, additional pharmacogenomic training during medical/graduate school, and a succinct interpretation of pharmacogenomic results included on laboratory reports. CONCLUSIONS The majority of participants agreed that adding certain actionable pharmacogenomic genes to the American College of Medical Genetics and Genomics SF list is reasonable; however, this was qualified with a need for additional resources to support implementation.
Collapse
Affiliation(s)
- Meghan N Bartos
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York
- Department of Genetics, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama
| | - Stuart A Scott
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York
- Department of Pathology, Stanford University, Stanford
- Clinical Genomics Laboratory, Stanford Health Care, Palo Alto, California, USA
| | - Ethylin Wang Jabs
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York
| | - Hetanshi Naik
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York
| |
Collapse
|
2
|
Knowledge, attitude, and practice towards pharmacogenomics among hospital pharmacists in Thailand. Pharmacogenet Genomics 2021; 30:73-80. [PMID: 32187156 DOI: 10.1097/fpc.0000000000000399] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND AND OBJECTIVES Pharmacogenomics (PGx) is the use of human genomic information to avoid toxicity and optimize efficacy of drug therapy in an individual. Hospital pharmacists are the key persons to facilitate the incorporation of PGx into clinical practice. PGx is relatively new to Thai hospital pharmacists. Therefore, this study aimed to evaluate the knowledge, attitude, and practice of Thai hospital pharmacists towards PGx implementation. MATERIALS AND METHODS We conducted a cross-sectional questionnaire-based survey among 600 hospital pharmacists in 21 hospitals across Thailand. The questionnaire consisted of 35 questions using comment boxes, Likert scales, and multiple choice answers. RESULTS The response rate was 20.5% (n = 123). Nearly half of the hospital pharmacists (46.3%) had low PGx knowledge score (<5 points), particularly for applied PGx knowledge in clinical situations. Concerns regarding PGx reimbursement, privacy issues, and discrimination were mentioned in this survey. However, most hospital pharmacists had positive attitude towards PGx service. Only 7% of hospital pharmacists had recommended or interpreted PGx tests in the past year. National PGx guidelines and government policies were considered the important factors for PGx implementation. Moreover, the most preferred learning format for PGx education was professional academic conferences. CONCLUSION Hospital pharmacists in Thailand had positive attitude towards PGx, despite limited experience and practice of PGx. PGx education to support an application of PGx knowledge in clinical situations is required. National PGx guidelines and government policies may need to be developed to address the concerns for reimbursement, privacy, and discrimination to ensure successful PGx implementation.
Collapse
|
3
|
Bartlett MJ, Shephard EA. The integration and interpretation of pharmacogenomics - a comparative study between the United States of America and Europe: towards better health care. Drug Metab Pers Ther 2016; 31:91-6. [PMID: 27269898 DOI: 10.1515/dmpt-2015-0044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Accepted: 04/06/2016] [Indexed: 12/27/2022]
Abstract
The study of pharmacogenomics has, by harnessing sequence information from human genomes, the potential to lead to novel approaches in drug discovery, an individualized application of drug therapy, and new insights into disease prevention. For this potential to be realized results need to be interpreted to the prescriber into a format which dictates an action. This mini review briefly describes the history, the regulatory environment, opinions towards, and implementation, integration and interpretation of pharmacogenomics in the United States of America and Europe. The article discusses also how interpretation of pharmacogenomics could move forward to better implementation in health care.
Collapse
|
4
|
Abstract
Background: The use of genome-guided drug therapy will certainly influence clinical practice within healthcare. However, in spite of the benefits of pharmacogenomic testing, little is known regarding what clinicians think about this promising technology. Objective: The purpose of article was to identify themes within the attitudes of nurses in the field of oncology. Materials & methods: The sample included 246 responses to an open-ended question. A thematic analysis of these responses was completed. Results: The analysis uncovered six themes. Conclusion: Therefore, future research on the assessment of attitudes of oncology nurses concerning pharmacogenomics should incorporate these themes.
Collapse
Affiliation(s)
- Crystal Dodson
- Division of Nursing, Winston-Salem State University, 601 S Martin Luther King Jr Drive, Winston-Salem, NC 27110, USA
| |
Collapse
|
5
|
Opinions, hopes and concerns regarding pharmacogenomics: a comparison of healthy individuals, heart failure patients and heart transplant recipients. THE PHARMACOGENOMICS JOURNAL 2014; 15:13-9. [PMID: 24980785 DOI: 10.1038/tpj.2014.29] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/21/2013] [Revised: 03/12/2014] [Accepted: 05/22/2014] [Indexed: 01/17/2023]
Abstract
It is not yet known whether healthy individuals and patients with a chronic disease have similar attitudes towards pharmacogenomics. Thus we conducted a survey of 175 healthy volunteers, 175 heart failure (HF) patients and 100 heart transplant recipients to compare their opinions on this subject. Most participants (>90%) stated that they would accept pharmacogenomic testing and expressed high hopes regarding its potential applications. Overall, interest for pharmacogenomics was shared equally among the three groups. In contrast, after adjusting for age, gender, education and income, healthy individuals were more likely to voice concerns about potential employment (P=0.008 vs HF, odds ratio (OR)=2.93, confidence interval (CI)=1.33-6.47; P=0.010 vs Transplant, OR=2.46, CI=1.24-4.90) and insurance discrimination (P=0.001 vs HF, OR=5.58, CI=2.01-15.48; P<0.001 vs Transplant, OR=4.98, CI=2.03-12.21) and were possibly more worried by confidentiality issues. These findings highlight the need for strict legislation and proper educational strategies directed at the general population to facilitate the clinical implementation of pharmacogenomics.
Collapse
|
6
|
Dressler LG, Deal AM, Patel J, Markey J, Riper MV, McLeod HL. Cancer pharmacogenomics, adoption by oncologists and patient benefit. Per Med 2014; 11:143-153. [DOI: 10.2217/pme.14.1] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Aim: The study aim was to understand physician experience and factors influencing the adoption of cancer pharmacogenomic (caPGx) testing by oncologists practicing in academic and nonacademic settings. Method: Anonymous paper surveys were distributed to oncologists practicing in North Carolina (USA). Results: Although 98% of oncologists see promise in utilizing PGx tests in their practice, few were comfortable with their knowledge (33%) or interpreting test results (37%). At one site, the survey was not distributed due to clinician unfamiliarity with the term ‘pharmacogenomics’. Compared with oncologists in academia, community oncologists were more likely to order the new Oncotype Dx™ test for colon cancer (33% vs 0; p = 0.0071), more likely to indicate future use of caPGx tests (94 vs 75%; p = 0.012) and less likely to have never ordered a caPGx test (2 vs 35%%; p < 0.001). Nearly every oncologist was interested in additional PGx education. Conclusion: A critical need exists to disseminate accurate and updated caPGx information to oncologists practicing in both academic and nonacademic settings.
Collapse
Affiliation(s)
- Lynn G Dressler
- Mission Health, Personalized Medicine Program, Fullerton Genetics Center, Asheville, NC 28803, USA
| | - Allison M Deal
- University of North Carolina, School of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
| | - Jai Patel
- Carolinas Medical Center, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC 28203, USA
| | - Janell Markey
- University of North Carolina, School of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
| | - Marcia Van Riper
- University of North Carolina, School of Nursing, Chapel Hill, NC 27599, USA
| | - Howard L McLeod
- Moffit Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
| |
Collapse
|
7
|
Munson AM, Harralson AF, Plack MM, Nickola TJ. Out-of-school genomics program for young women demystifies genomics and fosters interest in biomedical sciences. Pharmacogenomics 2014; 15:265-76. [DOI: 10.2217/pgs.14.5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Background: Pharmacogenomics (PGx) plays a critical role in personalized medicine; however, most healthcare practitioners lack the training and confidence in PGx required to fully utilize its potential. Although continuing education and inclusion of PGx into the professional curricula will begin to address this deficiency, PGx education at the secondary and postsecondary levels would demystify PGx and pique interest at an academic stage that is key to funneling PGx curious students into the science and healthcare pipeline earlier. Methods: This article describes the development and evaluation of a genomics outreach program targeted at young women in high school with the ultimate goal of recruiting students into an undergraduate PGx program and school of pharmacy. Results: This program increased participants’ genomics knowledge, influenced their careers interests, and imparted positive feelings towards a genomics-based and/or biomedical career. Conclusion: Genomics-based educational outreach programs geared towards secondary school students can increase interest in and confidence to pursue a PGx-centric degree/career. Original submitted 3 July 2013; Revision submitted 6 January 2014
Collapse
Affiliation(s)
- Amanda M Munson
- Department of Pharmacogenomics, Bernard J Dunn School of Pharmacy, Shenandoah University, Innovation Hall Suite 202, 45085 University Drive, Ashburn, VA 20147, USA
- Department of Pharmacology & Physiology, Pharmacogenomics Program, The George Washington University, Ross Hall Suite 640, 2300 Eye Street NW, Washington, DC 20037, USA
| | - Arthur F Harralson
- Department of Pharmacogenomics, Bernard J Dunn School of Pharmacy, Shenandoah University, Innovation Hall Suite 202, 45085 University Drive, Ashburn, VA 20147, USA
- Department of Pharmacology & Physiology, Pharmacogenomics Program, The George Washington University, Ross Hall Suite 640, 2300 Eye Street NW, Washington, DC 20037, USA
| | - Margaret M Plack
- Department of Physical Therapy & Health Care Sciences, The George Washington University, School of Medicine & Health Sciences, 900 23rd Street NW, Washington, DC 20037, USA
| | - Tracey J Nickola
- Department of Pharmacogenomics, Bernard J Dunn School of Pharmacy, Shenandoah University, Innovation Hall Suite 202, 45085 University Drive, Ashburn, VA 20147, USA
| |
Collapse
|
8
|
Patrinos GP, Baker DJ, Al-Mulla F, Vasiliou V, Cooper DN. Genetic tests obtainable through pharmacies: the good, the bad, and the ugly. Hum Genomics 2013; 7:17. [PMID: 23835256 PMCID: PMC3711749 DOI: 10.1186/1479-7364-7-17] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2013] [Accepted: 06/25/2013] [Indexed: 12/02/2022] Open
Abstract
Genomic medicine seeks to exploit an individual’s genomic information in the context of guiding the clinical decision-making process. In the post-genomic era, a range of novel molecular genetic testing methodologies have emerged, allowing the genetic testing industry to grow at a very rapid pace. As a consequence, a considerable number of different private diagnostic testing laboratories now provide a wide variety of genetic testing services, often employing a direct-to-consumer (DTC) business model to identify mutations underlying (or associated with) common Mendelian disorders, to individualize drug response, to attempt to determine an individual’s risk of a multitude of complex (multifactorial) diseases, or even to determine a person’s identity. Recently, we have noted a novel trend in the provision of private molecular genetic testing services, namely saliva and buccal swab collection kits (for deoxyribonucleic acid (DNA) isolation) being offered for sale over the counter by pharmacies. This situation is somewhat different from the standard DTC genetic testing model, since pharmacists are healthcare professionals who are supposedly qualified to give appropriate advice to their clients. There are, however, a number of issues to be addressed in relation to the marketing of DNA collection kits for genetic testing through pharmacies, namely a requirement for regulatory clearance, the comparative lack of appropriate genetics education of the healthcare professionals involved, and most importantly, the lack of awareness on the part of both the patients and the general public with respect to the potential benefits or otherwise of the various types of genetic test offered, which may result in confusion as to which test could be beneficial in their own particular case. We believe that some form of genetic counseling should ideally be integrated into, and made inseparable from, the genetic testing process, while pharmacists should be obliged to receive some basic training about the genetic tests that they offer for sale.
Collapse
Affiliation(s)
- George P Patrinos
- Department of Pharmacy, School of Health Sciences, University of Patras, University Campus, Rion, Patras, 26504, Greece.
| | | | | | | | | |
Collapse
|
9
|
Nickola TJ, Green JS, Harralson AF, O'Brien TJ. The current and future state of pharmacogenomics medical education in the USA. Pharmacogenomics 2013; 13:1419-25. [PMID: 22966890 DOI: 10.2217/pgs.12.113] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Healthcare professionals (e.g., physicians, physician assistants, pharmacists, nurses and genetic counselors) believe pharmacogenomics (PGx) is essential to personalized medicine; however, they still lack confidence prescribing, dosing, interacting with other healthcare professionals and counseling patients with regard to PGx. This is due to the inadequate incorporation of PGx content into professional curricula. Compared with other health professions, Doctor of Pharmacy programs have integrated more PGx content. Unlike other healthcare professionals, pharmacists have extensive training in pharmacology, drug selection, drug dosage, drug-drug interactions and are uniquely accessible to patients. We suggest pharmacists are the best poised to facilitate incorporating PGx into therapeutic decision-making. Based on our experience as undergraduate and pharmacy PGx educators, we further reflect on our experience educating future healthcare professionals on PGx.
Collapse
Affiliation(s)
- Tracey J Nickola
- Department of Pharmacology & Physiology, Pharmacogenomics Program, The George Washington University, Ross Hall Room 660A, 2300 Eye Street, NW Washington, DC 20037, USA
| | | | | | | |
Collapse
|
10
|
de Denus S, Letarte N, Hurlimann T, Lambert JP, Lavoie A, Robb L, Sheehan NL, Turgeon J, Vadnais B. An evaluation of pharmacists’ expectations towards pharmacogenomics. Pharmacogenomics 2013; 14:165-75. [DOI: 10.2217/pgs.12.197] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Background: Given their expertise in pharmacotherapy, pharmacists are well positioned to play a leading role in the implementation of pharmacogenomics in clinical practice. However, little is known about the opinions of pharmacists towards pharmacogenomics or their willingness to integrate this new field in their practice. Methods: We conducted a survey of 284 pharmacists practicing in the province of Québec (Canada) to describe the opinions, expectations and concerns of pharmacists toward pharmacogenomics. Results: Pharmacists were very hopeful regarding the potential role of pharmacogenomics. Moreover, more than 95% of responders would be willing to recommend pharmacogenomic testing. Nevertheless, only 7.7% of pharmacists currently felt comfortable advising patients based on pharmacogenomic test results. Accordingly, the majority of responders (96.6%) indicated that they would like to undertake continuing education related to pharmacogenomics. Conclusion: Pharmacists are extremely hopeful towards pharmacogenomic testing. Furthermore, a vast majority is willing to integrate these tests as part of their clinical practice. Proper education will be required if the integration of pharmacogenomics in patient care is to be optimal. Original submitted 21 September 2012; Revision submitted 16 November 2012
Collapse
Affiliation(s)
- Simon de Denus
- Montreal Heart Institute, Montreal, Canada
- Faculty of Pharmacy, Université de Montréal, Montreal, Canada
| | - Nathalie Letarte
- Faculty of Pharmacy, Université de Montréal, Montreal, Canada
- Department of Pharmacy, Centre Hospitalier de l’Université de Montréal, Montreal, Canada
| | - Thierry Hurlimann
- Faculty of Medicine, Department of Social & Preventive Medicine, Bioethics Programs, Université de Montréal, Montreal, Canada
| | | | - Annie Lavoie
- Faculty of Pharmacy, Université de Montréal, Montreal, Canada
- Sainte-Justine University Hospital Center, Montreal, Canada
| | - Laura Robb
- Montreal Heart Institute, Montreal, Canada
| | - Nancy L Sheehan
- Faculty of Pharmacy, Université de Montréal, Montreal, Canada
- McGill University Health Center, Montreal, Canada
| | - Jacques Turgeon
- Faculty of Pharmacy, Université de Montréal, Montreal, Canada
- Research Centre of the Université de Montréal Hospital Centre, Montreal, Canada
| | - Barbara Vadnais
- Faculty of Pharmacy, Université de Montréal, Montreal, Canada
- Department of Pharmacy, Maisonneuve-Rosemont Hospital, Montreal, Canada
| |
Collapse
|
11
|
Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin Genet 2012; 82:388-94. [PMID: 22698141 PMCID: PMC3440554 DOI: 10.1111/j.1399-0004.2012.01908.x] [Citation(s) in RCA: 198] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2012] [Revised: 05/30/2012] [Accepted: 06/04/2012] [Indexed: 11/29/2022]
Abstract
It is anticipated that as the range of drugs for which pharmacogenetic testing becomes available expands, primary care physicians (PCPs) will become major users of these tests. To assess their training, familiarity, and attitudes toward pharmacogenetic testing in order to identify barriers to uptake that may be addressed at this early stage of test use, we conducted a national survey of a sample of PCPs. Respondents were mostly white (79%), based primarily in community-based primary care (81%) and almost evenly divided between family medicine and internal medicine. The majority of respondents had heard of PGx testing and anticipated that these tests are or would soon become a valuable tool to inform drug response. However, only a minority of respondents (13%) indicated they felt comfortable ordering PGx tests and almost a quarter reported not having any education about pharmacogenetics. Our results indicate that primary care practitioners envision a major role for themselves in the delivery of PGx testing but recognize their lack of adequate knowledge and experience about these tests. Development of effective tools for guiding PCPs in the use of PGx tests should be a high priority.
Collapse
Affiliation(s)
- S B Haga
- Institute for Genome Sciences & Policy, Duke University, Durham, NC 27708, USA.
| | | | | | | | | |
Collapse
|
12
|
Bernhardt BA, Zayac C, Gordon ES, Wawak L, Pyeritz RE, Gollust SE. Incorporating direct-to-consumer genomic information into patient care: attitudes and experiences of primary care physicians. Per Med 2012; 9:683-692. [PMID: 23795206 DOI: 10.2217/pme.12.80] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
AIM Despite predictions of increased clinical applications, little is known about primary care providers' (PCPs') readiness to apply genomics to patient care. The aim was to assess PCPs' current experience with genetic testing, their assessment of the understandability and clinical utility of information in sample direct-to-consumer reports for genomic assessment of disease risk and warfarin dosing and attitudes toward genomic medicine. MATERIALS & METHODS A web-based survey of PCPs who are members of Knowledge Networks' Physician Consulting Network was conducted. RESULTS Of the 502 respondents (23.3% response rate), most ordered genetic tests infrequently. When presented with the direct-to-consumer genomic testing reports, most believed the reports were understandable, and would be willing to review results with a patient, and many believed the results would be helpful in patient management. CONCLUSION Despite limited experience with genetic tests, PCPs are open to helping patients understand genomic information. However, additional physician education is needed.
Collapse
Affiliation(s)
- Barbara A Bernhardt
- Division of Translational Medicine & Human Genetics, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, Penn Tower Room 1115, Philadelphia, PA 19104, USA ; Penn Center for the Integration of Genetic Healthcare Technologies, University of Pennsylvania, Philadelphia, PA 19104, USA
| | | | | | | | | | | |
Collapse
|
13
|
Haga SB, O'Daniel JM, Tindall GM, Mills R, Lipkus IM, Agans R. Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing. Clin Genet 2012; 82:115-20. [PMID: 22283474 PMCID: PMC3351546 DOI: 10.1111/j.1399-0004.2012.01848.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Pharmacogenetic (PGx) testing aims to improve therapeutic outcomes through tailoring treatment based on a patient's genetic risk for non-response and/or an adverse event. Given their expertise, geneticists could facilitate the use of PGx testing; however, the preparedness and perceived role of the clinical genetics community is unclear. To assess the attitudes, preparedness, and perceived roles of geneticists in the delivery of PGx testing, we conducted a survey of 1500 randomly selected board-certified genetic counselors and clinical geneticists in the United States [response rate: 37.8% (n = 516)]. Twelve percent of genetic counselors and 41% of clinical geneticists indicated that they had ordered or coordinated patient care for PGx testing, a seemingly high proportion at this early stage of adoption. Almost all respondents had some education on pharmacogenetics, although only 28% of counselors and 58% of clinical geneticists indicated they felt well-informed about PGx testing. About half of counselors (52%) and clinical geneticists (46%) felt they would play 'some' role in the delivery of PGx testing; 17 and 19%, respectively, felt that they would play 'no' or 'a little' role. At this early stage of PGx testing, the role of geneticists and genetic counselors is unclear. However, their experience may aid in readying PGx testing and informing delivery strategies into clinical practice.
Collapse
Affiliation(s)
- S B Haga
- Institute for Genome Sciences & Policy, Duke University, 304 Research Drive, Durham, NC 27708, USA.
| | | | | | | | | | | |
Collapse
|
14
|
Benzeroual KE, Shah B, Shinde S. Pharmacogenomics: assessing educational exposure, confidence in knowledge and training elements of pharmacists. Per Med 2012; 9:387-393. [DOI: 10.2217/pme.12.44] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Aim: This study assessed pharmacist’s knowledge and confidence in pharmacogenomics (PGx)-related concepts, and determined their needs with regard to education and training in PGx. Methods: A cross-sectional survey instrument was sent via postal mail to pharmacists (n = 319) who were randomly selected from the New York State database of licensed pharmacists. Descriptive and bivariate statistics were performed. Results: The response rate was 32% (n = 102). The majority (83%) of respondents had been exposed to basic concepts in genetics, while PGx was not an integral part of their education. Most respondents indicated being somewhat confident in their knowledge of PGx-related concepts. In addition, 64% of respondents reported being interested in attending 1–10 h of continuing education programs in PGx, and 42% of respondents indicated being interested in obtaining a certificate in PGx. Conclusion: Educational program development in the format of continuing education or certificate is needed to improve pharmacists’ education, confidence and training needs in PGx.
Collapse
Affiliation(s)
- Kenza E Benzeroual
- Department of Pharmaceutical Sciences, Arnold & Marie Schwartz College of Pharmacy & Health Sciences, Long Island University, NY, USA
| | - Bupendra Shah
- Department of Pharmaceutical Sciences, Arnold & Marie Schwartz College of Pharmacy & Health Sciences, Long Island University, NY, USA
| | - Shraddha Shinde
- Department of Pharmaceutical Sciences, Arnold & Marie Schwartz College of Pharmacy & Health Sciences, Long Island University, NY, USA
| |
Collapse
|